PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Anker, Stefan D.
TI  - Mid-Regional Pro-Adrenomedullin Test Predicts 90-Day Mortality after Heart Failure
DP  - 2009 Feb 01
TA  - MD Conference Express
PG  - 19--20
VI  - 8
IP  - 8
4099  - http://mdc.sagepub.com/content/8/8/19.short
4100  - http://mdc.sagepub.com/content/8/8/19.full
AB  - A novel biomarker, mid-regional pro-adrenomedullin (MR-proADM), has been shown to predict mortality among patients with heart failure better than the established biomarkers for prognosis that currently are available. MR-proADM was compared with brain natriuretic peptide (BNP) and NT-proBNP (a biologic fragment associated with BNP) in the BACH trial [NCT00537628], which is the largest biomarker study to be done in the setting of suspected heart failure.